REPCF — 0913693 BC Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | 116.41% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
0913693 B.C. Ltd., formerly RepliCel Life Sciences Inc., is a Canada-based company. The Company is not engaged in any business activities. It was previously engaged in developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function.
Directors
- David Hall NEC
- R. Lee Buckler PRE
- Simon Ma CFO (55)
- Rolf Hoffmann OTH (58)
- Gary Boddington DRC
- Peter Lewis IND
- Peter Lowry IND
- Andrew Schutte IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 22nd, 2011
- Public Since
- April 26th, 2004
- No. of Employees
- 1
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- Pink Sheets on Nasdaq
- Address
- 570 Granville St Suite 900, VANCOUVER, V6C 3P1
- Web
- https://www.replicel.com/
- Phone
- +1 6042488693
- Auditors
- Mao & Ying LLP
Upcoming Events for REPCF
Similar to REPCF
1399 Internet Technology Application
Pink Sheets on Nasdaq
9 Meters Biopharma
Pink Sheets on Nasdaq
Absolute Health and Fitness
Pink Sheets on Nasdaq
ACC Aviation Holdings
Pink Sheets on Nasdaq
Access-Power & Co
Pink Sheets on Nasdaq
FAQ
As of Today at 13:00 UTC, shares in 0913693 BC are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in 0913693 BC last closed at $0.00 and the price had moved by -95.1% over the past 365 days. In terms of relative price strength the 0913693 BC share price has underperformed the S&P500 Index by -95.53% over the past year.
There is no consensus recommendation for this security.
Find out more0913693 BC does not currently pay a dividend.
0913693 BC does not currently pay a dividend.
0913693 BC does not currently pay a dividend.
To buy shares in 0913693 BC you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in 0913693 BC had a market capitalisation of .
Here are the trading details for 0913693 BC:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: REPCF
Based on an overall assessment of its quality, value and momentum 0913693 BC is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 0913693 BC. Over the past six months, its share price has underperformed the S&P500 Index by -95.48%.
As of the last closing price of $0.00, shares in 0913693 BC were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The 0913693 BC PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
0913693 BC's management team is headed by:
- David Hall - NEC
- R. Lee Buckler - PRE
- Simon Ma - CFO
- Rolf Hoffmann - OTH
- Gary Boddington - DRC
- Peter Lewis - IND
- Peter Lowry - IND
- Andrew Schutte - IND